← Eichor
Condition: Cd34 Stem Cells Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cd34 Stem Cells

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
NA · 1 location(s) · NYU Langone Health · NCT06569082TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantat
Phase 1 · 2 location(s) · Stanford University · NCT03943238Apheresis of Patients With Immunodeficiency
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01212055Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT02438904Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched Wit
Phase 2 · 1 location(s) · Minovia Therapeutics Ltd. · NCT06017869A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
Phase 1/Phase 2 · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT07607197A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Particip
Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05757245Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05773729The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
Phase N/A · 1 location(s) · University Medical Centre Ljubljana · NCT07604467Autologous Gene Therapy for Artemis-Deficient SCID
Phase 1/Phase 2 · 1 location(s) · University of California, San Francisco · NCT03538899Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Phase 1/Phase 2 · 6 location(s) · Kamau Therapeutics · NCT04819841Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06896344Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)
Phase N/A · 1 location(s) · Northwell Health · NCT07186179Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Phase 2 · 4 location(s) · New York Medical College · NCT02675959Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00001405Gene Editing For Sickle Cell Disease
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT06506461Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells a
Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03520647CS-206 in Patients With Sickle Cell Disease
EARLY_Phase 1 · 1 location(s) · CorrectSequence Therapeutics Co., Ltd · NCT06565026Gene-Modified Stem Cell Therapy for Children With Autosomal Recessive Osteopetrosis (ARO)
Phase 1/Phase 2 · 1 location(s) · Fondazione Telethon · NCT07665021Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05776173Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
NA · 2 location(s) · Baylor College of Medicine · NCT01189786Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Us
Phase 2 · 2 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT01174108Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia
Phase 2 · 2 location(s) · Fondazione Telethon · NCT07680803Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation
Phase 1 · 1 location(s) · Columbia University · NCT04804891Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient D
Phase 1 · 2 location(s) · Apriligen, Inc. · NCT07476183Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06399107Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Partic
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06414889Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Phase 2 · 3 location(s) · Paul Szabolcs · NCT03630211Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia an
Phase 3 · 6 location(s) · Vertex Pharmaceuticals Incorporated · NCT05477563
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.